[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 218,471
  • Shares Outstanding, K 22,663
  • Annual Sales, $ 146,070 K
  • Annual Income, $ -196,040 K
  • EBIT $ -84 M
  • EBITDA $ -74 M
  • 60-Month Beta 0.83
  • Price/Sales 1.47
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 121.82% (-20.50%)
  • Historical Volatility 75.48%
  • IV Percentile 21%
  • IV Rank 7.33%
  • IV High 558.15% on 03/19/26
  • IV Low 87.31% on 04/10/26
  • Expected Move (DTE 2) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 26
  • Volume Avg (30-Day) 1,013
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 28,742
  • Open Int (30-Day) 25,349
  • Expected Range 9.49 to 9.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.25
  • Number of Estimates 2
  • High Estimate $-0.81
  • Low Estimate $-1.68
  • Prior Year $-4.32
  • Growth Rate Est. (year over year) +71.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.85 +37.37%
on 05/19/26
10.22 -7.93%
on 06/12/26
+1.74 (+22.69%)
since 05/15/26
3-Month
5.00 +88.20%
on 03/26/26
10.23 -8.01%
on 05/14/26
+0.86 (+10.06%)
since 03/16/26
52-Week
3.65 +157.79%
on 08/11/25
10.99 -14.38%
on 02/24/26
+4.87 (+107.27%)
since 06/16/25

Most Recent Stories

More News
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026

NEWTON, Mass. , June 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it will...

KPTI : 9.36 (-2.90%)
Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026

– New Data will Highlight a Post-Hoc Analysis from Phase 1 Portion of SENTRY Trial that Indicates Achievement of SVR35 with Selinexor plus Ruxolitinib May Predict Overall Survival –

KPTI : 9.36 (-2.90%)
Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achieving SVR35 at Week 24, versus Ruxolitinib, with a Consistent SVR35 Benefit Observed Across Prespecified...

KPTI : 9.36 (-2.90%)
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass. , June 1, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company...

KPTI : 9.36 (-2.90%)
Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation

– Event To Feature Dr. John Mascarenhas, Principal Investigator of the Phase 3 SENTRY Trial –

KPTI : 9.36 (-2.90%)
Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference

NEWTON, Mass. , May 28, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's...

KPTI : 9.36 (-2.90%)
Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts

Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear...

KPTI : 9.36 (-2.90%)
Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference,...

KPTI : 9.36 (-2.90%)
Karyopharm Therapeutics Q1 Earnings Call Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) said it entered 2026 with several near-term clinical and regulatory catalysts, led by new Phase 3 data in myelofibrosis and an expected midyear readout in endometrial...

KPTI : 9.36 (-2.90%)
Karyopharm Therapeutics: Q1 Earnings Snapshot

Karyopharm Therapeutics: Q1 Earnings Snapshot

KPTI : 9.36 (-2.90%)

Business Summary

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States.

See More

Key Turning Points

3rd Resistance Point 10.27
2nd Resistance Point 10.03
1st Resistance Point 9.84
Last Price 9.36
1st Support Level 9.40
2nd Support Level 9.17
3rd Support Level 8.97

See More

52-Week High 10.99
Last Price 9.36
Fibonacci 61.8% 8.19
Fibonacci 50% 7.32
Fibonacci 38.2% 6.45
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.